Tirzepatide received FDA approval for type 2 diabetes in May 2022 and for chronic weight management in November 2023, following extensive clinical evaluation through the SURPASS and SURMOUNT trial programs
Judge Marston appointed Stephenson and other experienced attorneys to serve on the Plaintiffs Executive Committee (PEC), which is responsible for coordinating litigation strategy, overseeing discovery, and advancing plaintiffs claims on a nationwide basis
It has potent effects on blood glucose by either stimulating glucose-induced insulin release or inhibiting glucagon secretion [8, 9], and suppresses appetite via receptors in the ventral tegmental area, the nucleus accumbens and the hypothalamus (Fig
doi:10.4103/ijt.ijt_54_23
With ongoing support, we ensure youre on track for long-term weight management
For people with diabetes, the threshold for treatment and treatment target has remained the same at the time of this publication and is 60 mL/min per 1.73 m by inducing glucosuria, and they were initially marketed for this purpose
